Elisity

Elisity delivers identity-based microsegmentation designed to stop ransomware and attacker lateral movement across IT, OT, and IoT environments. Its IdentityGraph technology pulls identity, behavior, traffic, and risk signals from more than 25 tools an organization already owns, builds a real-time record for every device on the network, and enforces least-privilege access policies through existing network infrastructure — enabling full microsegmentation in weeks rather than the months or years typical of hardware-based or agent-based approaches.

Founded in 2019 and headquartered in San Jose, California, Elisity reports 8,860% growth from 2021 to 2024 and counts Fortune 500 healthcare systems, global manufacturers, and pharmaceutical companies among its customers, including GSK, Main Line Health, Shaw Industries, and St. Luke’s University Health Network. The company has secured investment from Technology Crossover Ventures (TCV) and Chevron Technology Ventures, the latter notable as a strategic OT/industrial validation signal beyond typical enterprise IT buyers.

Microsegmentation is an established category with strong incumbents like Illumio and Zero Networks, but most require agents or significant network re-architecture. Elisity’s differentiation — agentless, identity-driven enforcement through existing switches and infrastructure — is a genuinely different deployment model, backed by named enterprise customers rather than only vendor claims, though independent, third-party efficacy testing is still limited.